Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC
Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.
Daniel J. George, MD, professor of Medicine, professor in Surgery, Duke Cancer Institute, discusses the use of niraparib (Zejula) for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA and ATM mutations.
The phase 2 Galahad trial (NCT02854436) evaluated niraparib in patients with a documented biallelic DNA-repair anomaly, including those with BRCA and ATM mutations, among other defects, George explains.
Niraparib demonstrated a high clinical response rate in this patient population, George continues. Additionally, both the objective response rate and duration of response were beneficial, George concludes.
